Literature DB >> 25157838

Reply: Measurement of serum suPAR is not ready for clinical use.

Jeroen Deegens1, Jack Wetzels1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25157838     DOI： 10.1038/nrneph.2014.113-c2

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  11 in total

1.  Serum-soluble urokinase receptor concentration in primary FSGS.

Authors:  Rutger J H Maas; Jack F M Wetzels; Jeroen K J Deegens
Journal:  Kidney Int       Date:  2012-05       Impact factor: 10.612

2.  suPAR is the circulating factor in some but not all FSGS.

Authors:  Howard Trachtman; Jochen Reiser
Journal:  Nat Rev Nephrol       Date:  2014-08-26       Impact factor: 28.314

3.  Glomerular disease: The search goes on: suPAR is not the elusive FSGS factor.

Authors:  Jeroen K Deegens; Jack F Wetzels
Journal:  Nat Rev Nephrol       Date:  2014-06-24       Impact factor: 28.314

4.  The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis.

Authors:  Björn Meijers; Rutger J H Maas; Ben Sprangers; Kathleen Claes; Ruben Poesen; Bert Bammens; Maarten Naesens; Jeroen K J Deegens; Ruth Dietrich; Markus Storr; Jack F M Wetzels; Pieter Evenepoel; Dirk Kuypers
Journal:  Kidney Int       Date:  2014-01-08       Impact factor: 10.612

5.  Serum soluble urokinase-type plasminogen activator receptor levels and idiopathic FSGS in children: a single-center report.

Authors:  Margret E Bock; Heather E Price; Lorenzo Gallon; Craig B Langman
Journal:  Clin J Am Soc Nephrol       Date:  2013-04-25       Impact factor: 8.237

6.  Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis.

Authors:  Changli Wei; Shafic El Hindi; Jing Li; Alessia Fornoni; Nelson Goes; Junichiro Sageshima; Dony Maiguel; S Ananth Karumanchi; Hui-Kim Yap; Moin Saleem; Qingyin Zhang; Boris Nikolic; Abanti Chaudhuri; Pirouz Daftarian; Eduardo Salido; Armando Torres; Moro Salifu; Minnie M Sarwal; Franz Schaefer; Christian Morath; Vedat Schwenger; Martin Zeier; Vineet Gupta; David Roth; Maria Pia Rastaldi; George Burke; Phillip Ruiz; Jochen Reiser
Journal:  Nat Med       Date:  2011-07-31       Impact factor: 53.440

7.  Serum-soluble urokinase receptor levels do not distinguish focal segmental glomerulosclerosis from other causes of nephrotic syndrome in children.

Authors:  Aditi Sinha; Jaya Bajpai; Savita Saini; Divya Bhatia; Aarti Gupta; Mamta Puraswani; Amit K Dinda; Sanjay K Agarwal; Shailaja Sopory; Ravindra M Pandey; Pankaj Hari; Arvind Bagga
Journal:  Kidney Int       Date:  2014-01-15       Impact factor: 10.612

8.  A multicenter cross-sectional study of circulating soluble urokinase receptor in Japanese patients with glomerular disease.

Authors:  Takehiko Wada; Masaomi Nangaku; Shoichi Maruyama; Enyu Imai; Kumi Shoji; Sawako Kato; Tomomi Endo; Eri Muso; Kouju Kamata; Hitoshi Yokoyama; Keiji Fujimoto; Yoko Obata; Tomoya Nishino; Hideki Kato; Shunya Uchida; Yoshie Sasatomi; Takao Saito; Seiichi Matsuo
Journal:  Kidney Int       Date:  2014-01-15       Impact factor: 10.612

9.  Podocyte effacement closely links to suPAR levels at time of posttransplantation focal segmental glomerulosclerosis occurrence and improves with therapy.

Authors:  Nada Alachkar; Changli Wei; Lois J Arend; Annette M Jackson; Lorraine C Racusen; Alessia Fornoni; George Burke; Hamid Rabb; Kavita Kakkad; Jochen Reiser; Michelle M Estrella
Journal:  Transplantation       Date:  2013-10-15       Impact factor: 4.939

10.  Soluble urokinase plasminogen activator receptor levels are elevated and associated with complications in patients with type 1 diabetes.

Authors:  S Theilade; S Lyngbaek; T W Hansen; J Eugen-Olsen; M Fenger; P Rossing; J L Jeppesen
Journal:  J Intern Med       Date:  2014-06-23       Impact factor: 8.989
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.